Sunday, 4 November 2007

08.00 – 09.00

The best abstracts for oral presentations

Chairs:	A. Alcaraz, Barcelona (ES)
	N. Maitland, York (GB)
	M. Baumann, Dresden (DE)

09.00 - 10.30

Pathways to hormone resistant prostate cancer

Chairs:	N. Maitland, York (GB)
	J. Schalken, Nijmegen (NL)

09.00 - 09.20

Potential targets in the apoptotic cascade

W. Watson, Dublin (IE)

09.20 - 09.40

The androgen receptor pathway in prostate cancer

J. Trapman, Rotterdam (NL)

09.40 - 10.00

Aberrant PI3K-PTEN-TOR signalling in cancer

R. Bernardi, New York (US)

10.00 - 10.20

Signalling and prostate cancer stem cells

N. Maitland, York (GB)

10.20 – 10.30

Discussion

10.30 - 11.00

Coffee break and poster viewing

11.00 - 12.30

Therapy in hormone resistant prostate cancer

Chairs:	M. Hussain, Detroit (US)
	C. Sternberg, Rome (IT)

11.00 - 11.20

Redefining response criteria for clinical trials

M. Hussain, Detroit (US)

11.20 - 11.40

Chemotherapy, when and why?

R. De Wit, Rotterdam (NL)

11.40 - 12.00

Aberaterone, methylation inhibitors and other novel targets in development

J. De Bono, Sutton, Surrey (GB)

12.00 - 12.20

Novel therapeutics in clinical trials

M. Eisenberger, Baltimore (US)

12.20 – 12.30

Discussion

12.30 - 13.00

Prostate cancer: What does the future hold?

12.30 – 12.40

Oncology

C. Sternberg, Rome (IT)

12.40 – 12.50

Radiotherapy

A. Zietman, Boston (US)

12.50 – 13.00

Urology

P-A. Abrahamsson, Malmö (SE)